Clinical Microbiology & Infection

A perspective on liposomal amphotericin B (AmBisome^®)
pp. 1-4(4)
Authors: Richardson, M.; de Pauw, B.

Changing epidemiology of systemic fungal infections
pp. 5-24(20)
Authors: Richardson, M.; Lass-Flörl, C.

Amphotericin B lipid preparations: what are the differences?
pp. 25-36(12)
Authors: Adler-Moore, J. P.; Proffitt, R. T.

Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients
pp. 37-45(9)
Authors: Einsele, H.; Loeffler, J.

New options for treatment of candidaemia in critically ill patients
pp. 46-54(9)
Authors: Ruhnke, M.; Hartwig, K.; Kofla, G.

New dosing strategies for liposomal amphotericin B in high-risk patients
pp. 55-64(10)
Author: Ellis, Michael

Combination antifungal therapy: a critical review of the evidence
pp. 65-70(6)
Author: Ostrosky-Zeichner, L.

Liposomal amphotericin B: what is its role in 2008?
pp. 71-83(13)
Authors: Lanternier, F.; Lortholary, O.